(Reuters) – Modern Inc. said Monday it had dosed the first patients in an initial study of a new vaccine candidate for COVID-19 for possible evaluation as a booster shot.
The company said its new candidate, mRNA-1283, could be stored in refrigerators instead of freezers, making it easier to distribute, especially in developing countries.
The initial phase study will assess the safety and immunogenicity of mRNA-1283 at three dose levels and will be administered to healthy adults either in single doses or in separate doses at 28 days, according to the company.
Last week, Moderna began dosing the first participants in a study that tested its candidates for the COVID-19 booster vaccine.
Reports of Manojna Maddipatla and Vishwadha Chander in Bengaluru; Edited by Shailesh Kuber and Anil D’Silva